"The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart "...
- Patient Information:
Details with Side Effects
Because thrombolytic therapy increases the risk of bleeding, Retavase® (reteplase) is contraindicated in the following situations:
- Active internal bleeding
- History of cerebrovascular accident
- Recent intracranial or intraspinal
- Intracranial neoplasm, arteriovenous
- Known bleeding diathesis
- Severe uncontrolled hypertension
Last reviewed on RxList: 9/15/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Retavase Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.